Results 181 to 190 of about 311,439 (263)

Heart-reactive antibody levels differentially associate with ventricular function in hereditary cardiomyopathies. [PDF]

BMC Cardiovasc Disord
Schiffer D, Afshar B, Grosser D, Pet J, Schmidbauer L, Bauser M, Ramos G, Boivin-Jahns V, Jahns R, Frantz S, Heuschmann P, Störk S, Gerull B, Beyersdorf N, Morbach C.   +14 more
europepmc   +1 more source

Causal correlations between inflammatory proteins and heart failure: A two‐sample Mendelian randomization analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1374-1385, April 2025.
Abstract Aims Inflammation plays a critical role in both the development and progression of heart failure (HF), which is a leading cause of morbidity and mortality worldwide. However, the causality between specific inflammation‐related proteins and HF risk remains unclear.
Xian‐Guan Zhu, Gui‐Qin Liu, Ya‐Ping Peng, Li‐Ling Zhang, Xian‐Jin Wang, Liang‐Chuan Chen, Yuan‐Xi Zheng, Xue‐Jun Xiang, Rui Qiao, Xian‐He Lin   +9 more
wiley   +1 more source

Non-Dilated Left Ventricular Cardiomyopathy: Exploring the Spectrum from Phenotype to Disease Entity. [PDF]

J Clin Med
Mangini F, Grimaldi M, Di Monaco A, Fortunato F, Vitulano N, Quadrini F, Dentamaro I, Guglielmo M, Spinelli F, Grimaldi V, Musella F, Sgarra L, Quarta S, Suma S, Biederman RWW, Calbi R.   +15 more
europepmc   +1 more source

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

Mitral annular disjunction is associated with markers of cardiomyopathy in pediatric Marfan syndrome. [PDF]

J Am Soc Echocardiogr
Doan KK, Weigand J, Stephens S, Harris K, Lara C, Parthiban A, Pignatelli R, Morris SA, Doan TT.   +8 more
europepmc   +1 more source

Diverse Clinical Spectrum of TTN-Truncation Variant Cardiomyopathy: A Case Series Illustrating Asymptomatic, Arrhythmic, Recurrent Takotsubo, and Inflammatory Phenotypes. [PDF]

Cureus
Jalilzadehbinazar M, Reiss CK, LaRue SJ, Gdowski MA, Rao AK.   +4 more
europepmc   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

The Multifaceted Role of the <i>FLNC</i> Gene in Hereditary Cardiomyopathies and Prognosis. [PDF]

Genes (Basel)
D'Apolito M, Ranaldi A, Gaudiano T, Maffione AB, Santacroce R, D'Andrea G, Iacoviello M, Margaglione M.   +7 more
europepmc   +1 more source

Myosin inhibitor therapy in Fabry cardiomyopathy with dynamic left ventricular outflow obstruction. [PDF]

Am Heart J Plus
Lau K, Petri N, Nordbeck P.
europepmc   +1 more source